Philips introduces Alturion ultrasound system with AI-powered workflows for high-volume clinical environments
Rhea-AI Summary
Philips (NYSE:PHG) launched the Alturion ultrasound system, featuring AI-powered workflows for high-volume clinical environments. Alturion recently received FDA 510(k) clearance and CE mark, enabling availability in the USA and Europe.
The system offers advanced imaging, Elevate Plus AI measurements, and integration within Philips’ connected ultrasound ecosystem, sharing a common interface and interchangeable transducers with EPIQ Elite and Affiniti systems. Compatibility with Collaboration Live supports real-time remote ultrasound support, training and consultation across care settings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- FDA 510(k) clearance and CE mark enable US and European availability
- AI-powered workflows and Elevate Plus AI measurements for abdominal ultrasound
- Shared user interface and interchangeable transducers with EPIQ Elite and Affiniti
- Designed for high-volume environments to help streamline exams and workflows
- Compatibility with Collaboration Live for real-time remote ultrasound support
Negative
- None.
News Market Reaction – PHG
On the day this news was published, PHG declined 2.30%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | AI toothbrush launch | Positive | +0.3% | Launch of AI-guided Sonicare DiamondClean 9900 Prestige electric toothbrush. |
| Jun 09 | AI impact report | Positive | +2.7% | U.S. Future Health Index report showing AI saving clinician time and boosting use. |
| Jun 09 | Global AI index | Positive | +2.7% | Global Future Health Index 2026 highlighting measurable AI benefits in healthcare. |
| Jun 02 | AI ultrasound clearance | Positive | -2.5% | FDA 510(k) clearance for Elevate Plus AI workflow on EPIQ Elite and Affiniti. |
| Apr 16 | AI CT clearance | Positive | -1.6% | FDA 510(k) clearance for AI-powered Spectral CT Verida imaging system. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged headlines have produced slightly positive average moves but with a mix of strong gains and notable declines.
Historical Comparison
Across 5 prior AI-tagged headlines, Philips shares typically saw modest reactions around 0.31%, with both positive and negative moves, suggesting AI product and clearance news has triggered only measured stock responses historically.
Regulatory & Risk Context
Reported short interest is relatively low, indicating limited squeeze potential and generally muted volatility pressure from short covering alone.
Key Terms
fda 510(k) clearance regulatory
ce mark regulatory
transducers technical
tele-ultrasound medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
July 8, 2026
Newest addition to the Philips ultrasound portfolio, Alturion recently received FDA 510(k) clearance and CE mark, expanding access to advanced imaging and workflow innovation across clinical settings
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the Alturion ultrasound system with AI-powered workflow built for high-volume settings. Available in the USA and Europe following FDA 510(k) clearance and CE mark certification, Alturion helps clinicians work more efficiently, deliver consistent results, and make confident clinical decisions.
As healthcare providers manage growing demand and increasing operational complexity, ultrasound teams need solutions that help improve efficiency without compromising quality. With the introduction of Alturion, Philips expands its ultrasound portfolio by bringing together advanced imaging, AI-powered workflows and a connected ecosystem that is designed to help streamline examinations and support consistency across users and clinical settings.
"At Philips, our goal is to develop technology that adapts to the realities of modern healthcare and helps care teams work more effectively in increasingly demanding clinical environments," said Jie Xue, Chief Business Leader, Precision Diagnosis at Philips. "Alturion was designed with that goal in mind, helping healthcare providers deliver high-quality care with greater efficiency and confidence."
Performance and usability across care settings
Alturion’s powerful processing architecture supports responsive performance and clear visualization across patients and exam types. With an expansive 24-inch monitor and a small footprint, the system enables easy movement from department to bedside and supports space utilization. Streamlined, intuitive workflows help reduce manual adjustments and exam time, helping providers manage high patient volumes, while a familiar user interface supports operational simplicity and consistency across care teams.
Alturion is the newest ultrasound system to include Elevate Plus with AI-powered measurements for abdominal ultrasound. AI-enabled capabilities help streamline acquisition, automate measurements, and support reproducibility. By helping reduce variability and save time, these tools can contribute to more consistent exams and support clinical decision-making.
A connected ultrasound ecosystem
Alturion fits within Philips’ connected ultrasound ecosystem, sharing a common user interface and interchangeable transducers that are compatible with EPIQ Elite and Affiniti systems. By enabling sonographers and clinicians to use the same transducers across multiple systems, healthcare organizations can help simplify training, accelerate onboarding and support consistent workflows across departments. Philips’ complete general imaging ultrasound portfolio is designed for upgradeability and is compatible with Collaboration Live, a tele-ultrasound capability that enables multiple users to connect in real time for remote support, training and consultation.
For more information on Alturion, please visit here.
For further information, please contact:
Jayme Maniatis
Philips Global External Relations
Tel.: 617-894-8368
E-mail: jayme.maniatis@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 64,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
